Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy.
Rovera G, Grimaldi S, Oderda M, Marra G, Calleris G, Iorio GC, Falco M, Grossi C, Passera R, Campidonico G, Mangia ML, Deandreis D, Faletti R, Ricardi U, Gontero P, Morbelli S. Rovera G, et al. Among authors: passera r. Diagnostics (Basel). 2024 Sep 5;14(17):1964. doi: 10.3390/diagnostics14171964. Diagnostics (Basel). 2024. PMID: 39272748 Free PMC article.
Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S. Porpiglia F, et al. Among authors: passera r. Eur Urol. 2017 Aug;72(2):282-288. doi: 10.1016/j.eururo.2016.08.041. Epub 2016 Aug 27. Eur Urol. 2017. PMID: 27574821 Free article. Clinical Trial.
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy.
Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. Deandreis D, et al. Among authors: passera r. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815. doi: 10.1007/s00259-020-04809-8. Epub 2020 Apr 20. Eur J Nucl Med Mol Imaging. 2020. PMID: 32314028
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival.
Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, Passera R, Liberini V, Scapoli P, Arena V, Racca M, Veltri A, Novello S, Deandreis D. Polverari G, et al. Among authors: passera r. Cancers (Basel). 2020 May 5;12(5):1163. doi: 10.3390/cancers12051163. Cancers (Basel). 2020. PMID: 32380754 Free PMC article.
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.
Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, Oderda M, Dall'Armellina S, Liberini V, Grimaldi S, Bellò M, Gontero P, Ricardi U, Deandreis D. Ceci F, et al. Among authors: passera r. Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268. doi: 10.1007/s00259-022-05741-9. Epub 2022 Feb 26. Eur J Nucl Med Mol Imaging. 2022. PMID: 35217883 Free PMC article.
188 results